<DOC>
	<DOCNO>NCT01586195</DOCNO>
	<brief_summary>This open-label , multicenter , single-agent , phase II study continuous oral Zelboraf ( vemurafenib ) patient locally-advanced , unresectable , stage IIIc metastatic melanoma activate exon 15 BRAF mutation V600E .</brief_summary>
	<brief_title>Study Of Zelboraf ( Vemurafenib ) Patients With Locally-Advanced , Unresectable , Stage IIIc Or Metastatic Melanoma Activating Exon 15 BRAF Mutations Other Than V600E</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Histologicallyconfirmed metastatic melanoma ( unresectable Stage IIIc IV ) activate BRAF mutation V600E Measurable disease ( defined RECIST , v1.1 ) Adequate recovery recent systemic local treatment cancer Adequate organ function Women childbearing potential male partner woman childbearing potential : agreement use prescribe contraception . Negative serum pregnancy test within 7 day commencement treatment premenopausal woman . Women either surgically sterile postmenopausal least 1 year eligible participate study Agreement donate blood blood product study least 6 month discontinuation vemurafenib ; male patient , agreement donate sperm study least 6 month discontinuation vemurafenib Invasive malignancy melanoma time enrollment within 2 year prior Pregnant breastfeed Concurrent antitumor therapy ( e.g. , chemotherapy , target therapy , radiation therapy , include participation experimental drug study ) Either concurrent condition history prior condition place patient unacceptable risk he/she treat study drug confounds ability interpret data study Ongoing cardiac dysrhythmia &gt; /= Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>